The current focus is improving lung-targeted delivery using optimized vectors and nanoparticles to achieve lasting CFTR correction with minimal immune response (First inhaled lentiviral gene therapy enters cystic fibrosis trial, 2025). This evidence concerns the gene CFTR and cystic fibrosis.